在特异性炎症性肌肉病变的分类和管理方面的进展
Joost Raaphorst1, Anneke J van der Kooi1, Christopher A Mecoli2
1Department of Neurology, Amsterdam Neuroscience, Amsterdam University Medical Centre, Amsterdam, Netherlands.
The Lancet. Neurology
|August 16, 2025
概括
异形性炎症性肌肉病是一种慢性免疫疾病. 在理解干扰素通路和B细胞向方面的进展为耐火性疾病患者提供了新的诊断生物标志物和治疗方法.
科学领域:
- 类风湿病学 类风湿病学
- 免疫学 免疫学 免疫学
- 遗传学 是一个遗传学.
背景情况:
- 异形性炎症性肌肉病 (IIM) 是一种免疫媒介疾病,在大多数成年人中具有慢性多系统性影响.
- 自体抗体有助于识别IIM亚型和严重并发症,如癌症或间歇性肺病.
- 多学科管理对于IIM患者至关重要.
研究的目的:
- 审查了解IIM病理生理学的最新进展.
- 为IIM突出新型诊断生物标志物和治疗策略.
- 讨论针对特定免疫路径的新兴治疗方法.
主要方法:
- 审查当前关于异常发炎性肌肉病变的文献.
- 对最近随机对照试验和病理生理学研究的分析.
- 探索新的治疗点和生物标志物.
主要成果:
- 干扰素诱导皮肤肌炎上调干扰素刺激基因,表明潜在的诊断和监测生物标志物.
- 针对干扰素途径 (单克隆自身抗体,JAK抑制剂) 的疗法正在开发中.
- B细胞向 (CD19-CAR T细胞疗法) 和T细胞向治疗对耐火性IIM有希望.
结论:
- 在了解干扰素通路和免疫细胞向方面取得的进展为IIM改善诊断和治疗铺平了道路.
- 干扰素诱导的转录可以作为疾病活动的有价值的生物标志物.
- 新型免疫疗法,包括CAR T细胞疗法,为耐火病例提供了新的希望.
相关概念视频
Inflammatory Bowel Disease IV: Pharmacological Management
189
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
189
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
420
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
420
Myocarditis III: Medical Management
16
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
16
Myocarditis II: Clinical Features and Diagnostic Tests
21
Myocarditis is an inflammation of the heart muscle. The symptoms vary widely, encompassing asymptomatic presentations to severe, acute manifestations.Clinical PresentationAsymptomatic cases: In some instances, myocarditis may be asymptomatic, with the infection resolving without intervention. These cases often go undetected unless discovered incidentally through diagnostic imaging or tests conducted for other reasons.General Early Symptoms: Early symptoms of myocarditis are non-specific and can...
21
Myasthenia Gravis: Overview and Treatment
1.9K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.9K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
232
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
232


